Previous 10 | Next 10 |
2024-02-02 07:13:49 ET More on Genmab, Pfizer, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree With The Market Pfizer Inc. (PFE) Q4 2023 Earnings Call Transcript U.S. govt. opens bids in Medica...
Validation is supported by data from Phase 3 innovaTV 301 trial Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has validated for review the marketing authorization application (MAA) of tisotumab ve...
2024-01-30 16:40:26 ET More on Johnson & Johnson Johnson & Johnson: Positioned To Receive Benefits Of Heavy R&D Investments Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy' Johnson & Johnson 2023 Q4 - Results -...
2024-01-23 16:29:32 ET Summary Genmab's appeal against Johnson & Johnson in an arbitration case has been denied, eliminating the potential upside for the company. Despite this setback, Genmab remains well positioned to create shareholder value through continued revenue growth ...
2024-01-23 07:56:29 ET More on Genmab, J&J, etc. Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off? Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition Genmab: 3 Trends To Track For A Strong 2024 And Beyo...
2024-01-23 07:08:06 ET More on Genmab, Johnson & Johnson, etc. Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off? Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition Genmab: 3 Trends To Track For A Strong...
2024-01-19 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-16 08:22:47 ET Losers: Allakos ALLK -54% announces on restructuring plans . Applied UV ( AUVI ) -18% announces receipt of significant orders in smart building technologies division . Applied Digital Corporation APLD -12% after Q2 earnings rele...
2024-01-11 23:20:33 ET Summary Genmab is a leading contender in the biotech industry with innovative technology, a robust pipeline, and strategic collaborations. Epcoritamab's growth is a positive trend to monitor, as it has shown impressive financial performance and secured regul...
2024-01-09 07:13:52 ET More on Genmab, Pfizer, etc. Pfizer Inc. (PFE) J.P. Morgan 42nd Annual Healthcare Conference (Transcript) Pfizer: 50% Down From The Highs, Generous Dividend, And Robust Balance Sheet Pfizer: Paying Too Much To Boost Revenues Pfizer wins...
News, Short Squeeze, Breakout and More Instantly...
Genmab A/S Company Name:
GMAB Stock Symbol:
NYSE Market:
Sixteen abstracts accepted for presentation and publication demonstrate depth and breadth of comprehensive epcoritamab development program Three oral presentations highlight novel data evaluating epcoritamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL), in combinati...
2024-05-11 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...